Zacks Investment Research
29 Jul 2026, 16:55 UTC · 1h ago
GSK Beats Q2 Earnings & Revenue Estimates, Announces Cost-Saving Plan
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
29 Jul 2026, 16:55 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
GSK reported Q2 2026 core earnings of $1.36 per ADS, beating the Zacks Consensus Estimate of $1.27. — Earnings beats typically trigger positive short-term price action as they signal better-than-expected operational performance.
+0.40GSK's quarterly revenues rose 5% to $11.28 billion, exceeding the consensus estimate of $10.79 billion. — Top-line growth and a revenue beat demonstrate strong market demand for the company's product portfolio.
+0.30The Specialty Medicines segment grew 14% and Oncology sales rose 17%, driven by strong demand for Jemperli and Ojjaara/Omjjara. — Strong growth in high-margin specialty and oncology areas indicates positive long-term momentum in the company's most valuable pipelines.
+0.30Continue reading
6 related stories
Top 1 mover · tap to explore
Sales in the General Medicines segment declined 9% on a year-over-year basis. — Significant declines in a core business segment suggest headwinds or loss of market share in general healthcare products.
-0.20Which stocks this story touches
The company beat both earnings and revenue estimates, with core earnings rising 9% year over year.
The company's partnered drug Juluca saw an 8% increase in sales.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Newsfile Corp
6h ago
